

## Immune Responses to Defined Antigens of *Mycobacterium bovis* in Cattle Experimentally Infected with *Mycobacterium kansasii*

W. R. Waters,<sup>1\*</sup> M. V. Palmer,<sup>1</sup> T. C. Thacker,<sup>1</sup> J. B. Payeur,<sup>2</sup> N. B. Harris,<sup>2</sup> F. C. Minion,<sup>3</sup>  
R. Greenwald,<sup>4</sup> J. Esfandiari,<sup>4</sup> P. Andersen,<sup>5</sup> J. McNair,<sup>6</sup> J. M. Pollock,<sup>6</sup> and K. P. Lyashchenko<sup>4</sup>

United States Department of Agriculture, Agricultural Research Service, National Animal Disease Center, Bacterial Diseases of Livestock Research Unit, Ames, Iowa<sup>1</sup>; USDA, Animal and Plant Health Inspection Service (APHIS), Veterinary Services, National Veterinary Services Laboratory, Mycobacteria and Brucella Section, Ames, Iowa 50010<sup>2</sup>; Iowa State University, College of Veterinary Medicine, Department of Veterinary Microbiology and Preventive Medicine, Ames, Iowa 50011<sup>3</sup>; Chembio Diagnostic Systems, Inc., Medford, New York<sup>4</sup>; Statens Serum Institut, Copenhagen, Denmark<sup>5</sup>; and Bacteriology Department, Veterinary Sciences Division, Stormont, Belfast, United Kingdom<sup>6</sup>

Received 10 February 2006/Returned for modification 21 March 2006/Accepted 24 March 2006

**Cross-reactive responses elicited by exposure to nontuberculous mycobacteria often confound the interpretation of antemortem tests for *Mycobacterium bovis* infection of cattle. The use of specific proteins (e.g., ESAT-6, CFP-10, and MPB83), however, generally enhances the specificity of bovine tuberculosis tests. While genes for these proteins are absent from many nontuberculous mycobacteria, they are present in *M. kansasii*. Instillation of *M. kansasii* into the tonsillar crypts of calves elicited delayed-type hypersensitivity and in vitro gamma interferon and nitrite concentration responses of leukocytes to *M. avium* and *M. bovis* purified protein derivatives (PPDs). While the responses of *M. kansasii*-inoculated calves to *M. avium* and *M. bovis* PPDs were approximately equivalent, the responses of *M. bovis*-inoculated calves to *M. bovis* PPD exceeded their respective responses to *M. avium* PPD. The gamma interferon and nitrite responses of *M. kansasii*-inoculated calves to recombinant ESAT-6–CFP-10 (rESAT-6–CFP-10) exceeded corresponding responses of noninoculated calves as early as 15 and 30 days after inoculation, respectively, and persisted throughout the study. The gamma interferon and nitrite responses of *M. bovis*-inoculated calves to rESAT-6–CFP-10 exceeded the corresponding responses of *M. kansasii*-inoculated calves beginning 30 days after inoculation. By using a lipoarabinomannan-based enzyme-linked immunosorbent assay, specific serum antibodies were detected as early as 50 days after challenge with *M. kansasii*. By a multiantigen print immunoassay and immunoblotting, serum antibodies to MPB83, but not ESAT-6 or CFP-10, were detected in *M. kansasii*-inoculated calves; however, responses to MPB83 were notably weaker than those elicited by *M. bovis* infection. These findings indicate that *M. kansasii* infection of calves elicits specific responses that may confound the interpretation of bovine tuberculosis tests.**

*Mycobacterium bovis*, a member of the *M. tuberculosis* complex, has a wide host range, is infectious to humans, and is the most common cause of tuberculosis (TB) in cattle. The presence of wildlife reservoirs (e.g., various deer species in the United Kingdom and the United States, the Eurasian badger in the United Kingdom, and brush-tailed possums in New Zealand) hinder efforts to eradicate TB within cattle and captive deer herds in developed countries. In Africa, bovine TB is rapidly spreading through Cape buffalo populations as well as other hoofstock, nonhuman primates, and various mammalian predators (23). Most notably, up to 90% of lions in areas of TB endemicity are *M. bovis* infected, likely due to infection rate amplification from predation on infected prey. In humans, recent TB outbreaks in several U.S. cities are linked with the ingestion of *M. bovis*-infected, nonpasteurized cheese from Mexico (47). Regardless of the host, the implications of TB diagnosis include regulatory action, public health concerns, movement restriction, isolation of affected individuals, and serious health issues, thus emphasizing the need for accurate diagnosis. The tests most widely used for the detection of TB

in humans and cattle include the measurement of delayed-type hypersensitivity (i.e., skin testing) to purified protein derivative (PPD) and an in vitro assay for gamma interferon (IFN- $\gamma$ ) concentrations produced in response to PPD stimulation (Quantiferon; Cellestis, Inc., Valencia, Calif.; and Bovigam; Pfizer Animal Health, Kalamazoo, Mich.). A major limitation of PPD-based tests is cross-reactivity due to responses induced upon exposure to related bacteria, principally other nontuberculous “environmental” mycobacteria.

*Mycobacterium kansasii* is not included in the *M. tuberculosis* complex, yet it may cause disease in otherwise healthy individuals, albeit infrequently, that is indistinguishable clinically from *M. tuberculosis* infection (2, 3, 14, 15). A culture positive for *M. kansasii* from humans is not indicative of disease, as the organism may be isolated from healthy individuals, and human-to-human transmission is not documented (1). A relatively high rate of human infection has been reported in certain locales within the United States, central Europe, southeast United Kingdom, and southern part of The Netherlands, potentially associated with heavy air pollution (1, 2). As with humans, *M. kansasii* infection of cattle is exceedingly rare and often associated with lesions of the respiratory tract and associated lymph nodes, diagnosed postmortem (B. Harris, personal observations). Disease management of *M. kansasii* infection is often complicated by the false interpretation of tests

\* Corresponding author. Mailing address: United States Department of Agriculture, Agricultural Research Service, National Animal Disease Center, P.O. Box 70, Ames, IA 50010-0070. Phone: (515) 663-7756. Fax: (515) 663-7458. E-mail: rwaters@nadc.ars.usda.gov.

presumptive for *M. tuberculosis* complex, evoking further diagnostic and epidemiological investigations and action. The use of defined antigens (e.g., early secretory antigenic target-6 [ESAT-6] and culture filtrate protein-10 [CFP-10]) generally enhances the differentiation of immune responses to *M. tuberculosis* complex organisms from those elicited by nontuberculous mycobacteria (2, 5, 8, 33, 34, 36, 40, 45). The *esat-6* and *cfp-10* genes are located in region of difference 1, an area of the virulent *M. tuberculosis* complex genome not present in the vaccine strain *M. bovis* bacille Calmette-Guérin (BCG) and most other nontuberculous mycobacteria. Unfortunately, the *esat-6* and *cfp-10* genes as well as the *esat-6* family genes TB10.4, TB10.3, and TB12.9 are also present in *M. kansasii* and are of significant homology (88% to 90% nucleotide homology and >95% amino acid homology) to the respective genes within *M. tuberculosis* complex organisms (2, 18, 19, 21, 37, 39). Additionally, *M. kansasii* contains a gene encoding MPB83 (41), a cell surface immunodominant antibody target used for the "specific" diagnosis of *M. bovis* infection of cattle (28) and several other wildlife reservoirs (e.g., the Eurasian badger [20] and white-tailed deer [46]). It may be anticipated that sensitization and/or infection with *M. kansasii* would result in antibody and cell-mediated responses that potentially confound the interpretation of TB tests based on either specific antigens (i.e., ESAT-6, CFP-10, or MPB83) or complex antigens (e.g., tuberculin, whole-cell sonicates, or culture filtrates). Indeed, humans with clinical disease resulting from *M. kansasii* infection have detectable IFN- $\gamma$  concentration responses to recombinant and peptide mixes of ESAT-6 and CFP-10, albeit at a much lower rate and level than *M. tuberculosis*-infected individuals (4). The impact of *M. kansasii* sensitization without the induction of clinical disease on TB diagnostic tests, however, is unclear.

The primary objective of the present study was to evaluate the immune response induced by the inoculation of calves with the subtype of *M. kansasii* associated with clinical disease in humans, subtype 1 (1, 32), to determine both the virulence in cattle and the potential for interference with the interpretation of bovine TB tests. A large challenge dose was used for *M. kansasii* inoculation to increase the potential for the generation of a lesion(s) and the induction of an immune response to mycobacterial antigens. In regard to adaptive immunity, the primary goal was the qualitative assessment of the response particularly to *Mycobacterium* TB-specific antigens, as a cross-reactive response may condemn an individual or a herd of animals. Cell-mediated and antibody responses against defined mycobacterial antigens were compared to those elicited by *M. bovis* infection. The implications of these studies may be important for the interpretation of new or existing TB tests, where exposure to *M. kansasii* without elicitation of disease evokes a potentially confounding response.

#### MATERIALS AND METHODS

**Calves, challenge inoculum, and necropsy.** Twenty-three male Holstein calves of approximately 3 months of age were obtained from a TB-free herd in Wisconsin and housed at the National Animal Disease Center in Ames, Iowa, according to institutional guidelines and approved animal care and use protocols. Treatment groups included *M. bovis*-inoculated ( $n = 9$ ), *M. kansasii*-inoculated ( $n = 4$ ), and noninoculated ( $n = 10$ ) calves. For experimental infection, the challenge inoculum (diluted in 0.2 ml of 0.15 M phosphate-buffered saline, pH 7.2 [PBS]) was instilled directly into both tonsillar crypts of sedated calves, as

described for the inoculation of white-tailed deer (31). Challenge dosages were  $4 \times 10^8$  CFU for *M. bovis* and  $4 \times 10^8$  CFU for *M. kansasii*. The strain of *M. bovis* used for the challenge inoculum (95-1315; USDA, Animal Plant and Health Inspection Service [APHIS]) was originally isolated from a white-tailed deer in Michigan (38). The strain of *M. kansasii* (03-6931; USDA, APHIS) was originally isolated from a pyogranulomatous lymph node detected upon routine TB surveillance at an abattoir in Pennsylvania. Challenge inocula were prepared as previously described (7). Two weeks prior to inoculation, the cattle were moved from an outdoor pen into climate-controlled rooms within either biosafety level 3 (*M. bovis*-inoculated cattle) or biosafety level 2 (*M. kansasii*-inoculated and noninoculated cattle, with separate facilities for each of these two groups) confinement facilities. Approximately 4.5 months after inoculation, all cattle were euthanized by intravenous injection of sodium pentobarbital (Fort Dodge Animal Health, Fort Dodge, Iowa) and examined. Various tissues were collected (tonsil, lung, liver, spleen, and lung-associated, head-associated, mesenteric, and prefemoral lymph nodes) for bacteriologic culture and microscopic examination as described previously (7, 45).

***M. kansasii* genotypic characterization.** The 16S-23S rRNA gene internal transcribed spacer (ITS) region of strain 03-6931 was amplified by using the primers ITS-F (5'-AAG TCG TAA CAA GGT ARC CG-3') and ITS-R (5'-YYG CCA AGG CAT CCA CC-3'). For this step, 2  $\mu$ l of heat-deactivated bacteria (heated to 80°C for 30 min) was added to the PCR mix containing 10 $\times$  buffer, 5% dimethyl sulfoxide (Sigma, St. Louis, Mo.), 1.5 mM MgCl<sub>2</sub>, 0.2 mM each deoxynucleoside triphosphate, 0.4 mM of each primer, and 1.25 U *Taq* polymerase (Invitrogen, Carlsbad, Calif.). Thermocycling conditions were as follows: an initial denaturation step at 94°C for 3 min followed by 30 cycles of denaturation at 94°C for 1 min, annealing at 55°C for 2 min, with extension at 72°C for 2 min, and a final extension step at 72°C for 5 min. Sequencing was performed with a CEQ 8000 cycle sequencer (Beckman-Coulter, Fullerton, Calif.). The complete ITS region was aligned with previously published ITS sequences from the five subtypes of *M. kansasii* (1) using the MegAlign v. 6.1 program (DNASTAR, Inc., Madison, Wis.).

**Tuberculin skin test procedures.** Two months after inoculation, cattle were tested for in vivo responsiveness to mycobacterial antigens using the caudal fold tuberculin skin test (CFT). The thickness of the right caudal fold (the fold of skin on either side of the tail head) was measured using calipers, injected intradermally with 0.1 ml (100  $\mu$ g) of *M. bovis*-derived PPD, and measured again 72 h after injection. Four months after inoculation, all inoculated cattle and five of the noninoculated cattle received a comparative cervical skin tuberculin test (CCT). The other five noninoculated calves received a CCT 1 week after the CFT; however, responses (i.e., serological, in vitro cellular, and in vivo cellular) did not differ between the two groups of noninoculated calves, so for the purposes of the present study, responses of the noninoculated calves are included in the same group. For the CCT, 0.1 ml (100  $\mu$ g) of *M. bovis* PPD and 0.1 ml (40  $\mu$ g) of *M. avium* PPD were administered at separate clipped sites in the midcervical region, according to guidelines described in the USDA, APHIS circular 91-45-01(39a). As with the CFT, skin thickness was measured with calipers prior to PPD administration and 72 h after injection. All PPDs for skin test procedures were obtained from the Brucella and Mycobacterial Reagents section of the National Veterinary Services Laboratory, Ames, Iowa.

**Mononuclear cell culture and blastogenesis.** Peripheral blood mononuclear cells (PBMC) were isolated from buffy coat fractions of peripheral blood collected in 2 $\times$  acid citrate dextrose (9). Wells of 96-well round-bottom microtiter plates (Falcon; Becton-Dickinson, Lincoln Park, N.J.) were seeded with  $2 \times 10^5$  mononuclear cells in a total volume of 200  $\mu$ l per well. The medium was RPMI 1640 supplemented with 25 mM HEPES buffer, 100 units/ml penicillin, 0.1 mg/ml streptomycin, 50  $\mu$ M 2-mercaptoethanol (Sigma), and 10% (vol/vol) fetal bovine serum. Wells contained medium plus 5  $\mu$ g/ml *M. bovis* PPD (CSL Limited), 5  $\mu$ g/ml *M. avium* PPD (CSL Limited), 1  $\mu$ g/ml rESAT-6-CFP-10, or medium alone (no stimulation). Leukocyte cultures were incubated for 6 days at 37°C in 5% CO<sub>2</sub> in air, as described previously by our group (44, 45) and others (40). After 6 days, 0.5  $\mu$ Ci of [*methyl*-<sup>3</sup>H]thymidine (specific activity, 6.7 Ci mmol<sup>-1</sup>; Amersham Life Science, Arlington Heights, Ill.) in 50  $\mu$ l of medium was added to each well, and cells were incubated for an additional 20 h. Well contents were harvested onto fiber filters with a 96-well plate harvester (EG & G Wallac, Gaithersburg, Md.), and the incorporated radioactivity (in counts per minute [cpm]) was measured by liquid scintillation counting. Treatments were run in triplicate. Data are presented as the mean ( $\pm$ standard error) cpm for stimulated samples minus the mean cpm for samples receiving medium alone (i.e.,  $\Delta$ cpm) for each treatment group (i.e., noninoculated and *M. kansasii*- and *M. bovis*-inoculated cattle).

**Griess reaction assay.** Culture supernatants (72 h) were harvested from replicate cultures (see the mononuclear cell culture procedure in the preceding

paragraph) for analysis of nitrite. The amount of nitrite, the stable oxidation product of nitric oxide (NO), within culture supernatants is a correlate of the amount of NO produced by cells in culture. Nitrite was measured using the Griess reaction assay (35), performed in 96-well microtiter plates (Immunolon 2; Dynatech Laboratories, Inc., Chantilly, VA). Culture supernatant (100  $\mu$ l) was mixed with 100  $\mu$ l of Griess reagent (0.5% sulfanilamide; Sigma) in 2.5% phosphoric acid (Mallinckrodt Chemicals, Inc., Paris, Kentucky) and 0.05% *N*-(1-naphthyl) ethylenediamine dihydrochloride (Sigma). The mixture was incubated at 21°C for 10 min. Absorbencies of test and standard samples at 550 nm were measured using an automated enzyme-linked immunosorbent assay (ELISA) plate reader. Samples were diluted in culture medium (RPMI 1640 medium with 2 mM L-glutamine and 10% [vol/vol] fetal bovine serum). Absorbencies of standards and test samples were converted to ng/ml of nitrite by comparing them to absorbencies of sodium nitrite standards (Fisher Chemicals, Fair Lawn, N.J.) within a linear curve fit. Assays were run on three sets of pooled triplicates for each treatment.

**IFN- $\gamma$  assay.** Heparinized blood samples were dispensed in 1.5-ml aliquots into individual wells of a 24-well plate (Falcon 353047; Becton Dickinson and Company, Franklin Lakes, N.J.). Wells contained whole blood plus 20  $\mu$ g/ml *M. bovis* PPD (Pfizer Animal Health), 20  $\mu$ g/ml *M. avium* PPD (Pfizer Animal Health), and 1  $\mu$ g/ml rESAT-6-CFP-10 (29, 45) or medium alone (no stimulation). Blood cultures were incubated for 24 h, and plasma was harvested and stored at -80°C. IFN- $\gamma$  concentrations in stimulated plasma were determined using a commercial ELISA-based kit (Bovigam; Pfizer Animal Health). Absorbencies of standards and test samples were read at 450 nm using an ELISA plate reader (Molecular Devices, Menlo Park, Calif.). Concentrations (ng/ml) of test samples were quantified by comparing the absorbencies of test samples with the absorbencies of standards within a linear curve fit. Duplicate samples for individual treatments were analyzed.

**ELISA of *M. bovis* LAM.** Lipoarabinomannan (LAM)-enriched mycobacterial antigen was prepared from *M. bovis* strain 95-1315 as described previously (42). Briefly, bacilli harvested from 4-week-old cultures were sonicated in PBS, further disrupted with 0.1- to 0.15-mm glass beads (Biospec Products, Bartlesville, Okla.) in a bead beater (Biospec Products), centrifuged, filtered (0.22  $\mu$ m), digested in a 1-mg/ml proteinase K (Roche Molecular Biochemicals, Indianapolis, Ind.) solution (50 mM Tris, 1 mM CaCl<sub>2</sub> buffer, pH 8.0) for 1 h at 50°C, and stored at -20°C. Immulon II 96-well microtiter plates (Dynatech, Chantilly, Va.) were coated with 100  $\mu$ l/well (8  $\mu$ g/well) antigen diluted in a carbonate/bicarbonate coating buffer (pH 9.6). Antigen-coated plates, including control wells containing coating buffer alone, were incubated for 20 h at 4°C. Plates were washed three times with 200  $\mu$ l/well PBS containing 0.05% Tween 20 (PBST; Sigma) and blocked with 200  $\mu$ l/well of a commercial milk diluent/blocking solution (Kirkegaard & Perry Laboratories, Inc., Gaithersburg, Md.). Wells were washed nine times with 200  $\mu$ l/well PBST and incubated for 1 h at 37°C with 100  $\mu$ l/well of peroxidase-labeled antibody immunoglobulin G heavy and light chains (goat origin; Kirkegaard & Perry Laboratories, Inc.) diluted 1:10,000 in PBS plus 0.1% gelatin. Wells were washed nine times with 200  $\mu$ l/well PBST and incubated for 4.5 min at room temperature with 100  $\mu$ l/well of SureBlue Microwell peroxidase substrate (Kirkegaard & Perry Laboratories, Inc.). The reaction was stopped by the addition of 100  $\mu$ l/well of 0.18 M sulfuric acid, and the absorbency (at 450 nm) of individual wells was measured using an automated ELISA plate reader (Molecular Devices, Menlo Park, Calif.). The sample/positive (S/P) ratios of test samples were calculated from absorbency values using the following formula: sample - negative control/positive control - negative control.

**Immunoblot assay.** Electrophoresis and immunoblot assays were performed using previously described procedures (6) with the following modifications. Comparisons of the reactivities of serial serum samples against rMPB83 antigen were conducted using a slot blotting device (Bio-Rad, Richmond, Calif.). Antigen was electrophoresed through preparative 12% (wt/vol) polyacrylamide gels and transferred to nitrocellulose filters. These filters were placed in a blocking solution consisting of PBST and 2% (wt/vol) bovine serum albumin (PBST-BSA). After being blocked, the filters were placed into the slot blot device, and individual sera, diluted 1:400 in PBST-BSA, were added to independent slots. After a 2-h incubation with gentle rocking, blots were washed three times with PBST and incubated with peroxidase-conjugated antibody immunoglobulin G (Kirkegaard & Perry Laboratories) diluted 1:40,000 in PBST-BSA for 1.5 h. Blots were again washed three times with PBST and developed for chemiluminescence in SuperSignal detection reagent (Pierce Chemical Co.).

**MAPIA.** The following recombinant antigens of *M. bovis* were purified to near homogeneity as polyhistidine-tagged proteins (Rv designations in parentheses are according to the classification of Cole et al. [12]): ESAT-6 (Rv3875) and CFP-10 (Rv3874) (produced at the Statens Serum Institut, Copenhagen, Denmark) and MPB59 (Rv1886c), MPB64 (Rv1980c), MPB70 (Rv2875), and MPB83

(Rv2873) (produced at the Veterinary Sciences Division, Stormont, Belfast, United Kingdom) (25). Alpha-crystallin (Acr1 [Rv3391]) and the 38-kDa protein PstS1 (Rv0934) were purchased from Standard Diagnostics, Seoul, Republic of Korea. The polyprotein fusions CFP-10-ESAT-6 and Acr1-MPB83 were constructed by overlapping PCR, using gene-specific oligonucleotides to amplify the genes from *M. tuberculosis* H37Rv chromosomal DNA. The fused polygene PCR products were cloned into the pMCT6 *Escherichia coli* expression vector using SmaI/BamHI restriction enzymes. The polyproteins were purified to near homogeneity by exploiting the polyhistidine tag encoded by the vector. The *M. bovis* culture filtrate was obtained from a field strain of *M. bovis* (T/91/1378; Veterinary Sciences Division, Belfast, United Kingdom) cultured in synthetic Sauton's medium. The multiantigen print immunoassay (MAPIA) was performed as described previously (26). Briefly, antigens were immobilized on a nitrocellulose membrane (Schleicher & Schuell, Keene, N.H.) at a protein concentration of 0.05 mg/ml by using a semiautomated airbrush printing device (Linomat IV, Camag Scientific, Inc., Wilmington, Del.). The membrane was cut perpendicular to the antigen bands into 4-mm-wide strips. Strips were blocked for 1 h with 1% nonfat skimmed milk in PBS with 0.05% Tween 20 and then incubated for 1 h, with serum samples diluted 1:40 in blocking solution. After they were washed, the strips were incubated overnight with peroxidase-conjugated protein G (Sigma) diluted 1:1,000, followed by another washing step. Cattle antibodies bound to printed antigens were visualized with 3,3',5,5'-tetramethyl benzidine (Kirkegaard & Perry Laboratories). Results were also evaluated by semiquantitative densitometry using Scion Image (version Beta 4.0.2).

**Statistics.** Data were analyzed by one-way analysis of variance followed by a Tukey-Kramer multiple-comparison test using a commercially available statistics program (InStat 2.00; GraphPAD Software, San Diego, Calif.). Pearson's product-moment correlations were computed between IFN- $\gamma$  concentrations in *M. avium* and *M. bovis* PPD-stimulated plasma samples.

## RESULTS

***Mycobacterium kansasii* genotyping and infection status.** The ITS sequence obtained for the field strain was a 100% match to the ITS region from *M. kansasii* subtype 1 (1), confirming that the isolate used in these studies belongs to the subgroup most commonly associated with clinical disease in humans. Despite these associations (i.e., between the subtype 1 group and the original isolation from a pyogranuloma), neither gross or microscopic lesions nor mycobacteria were detected in tissues from 3-month-old calves whose tonsillar crypts had been inoculated with  $4 \times 10^8$  CFU of *M. kansasii*. In sharp contrast, *M. bovis* inoculation resulted in tuberculous lesions in tonsils, lungs, liver, and medial retropharyngeal, mandibular, parotid, mediastinal, tracheobronchial, and mesenteric lymph nodes (all *M. bovis*-inoculated animals had lesions, but each animal did not have lesions in each of these organs). Lesions and mycobacteria were not detected in tissues from noninoculated (control) animals.

**Delayed-type-hypersensitivity response.** Exposure of cattle to nontuberculous mycobacteria may result in false-positive tuberculin skin test reactions (22). As expected, the injection of *M. bovis* PPD for the CFT resulted in palpable reactions in all *M. kansasii*-inoculated cattle, indicating sensitization without persistent infection (i.e., no lesions were detected upon necropsy). All *M. bovis*-inoculated and 1/10 noninoculated animals also had palpable reactions to *M. bovis* PPD upon CFT. Ranking of the mean responses by each of the groups resulted in *M. bovis*-inoculated cattle having stronger reactions than *M. kansasii*-inoculated cattle and *M. kansasii* cattle having stronger reactions than noninoculated cattle (Fig. 1A). Within the United States, cattle with CFT reactions are considered "TB suspects" and retested using either the CCT or Bovigam assay (Pfizer Animal Health). All *M. bovis*-infected cattle in the present study were determined to be "reactors" by CCT




FIG. 1. Delayed-type-hypersensitivity responses to *M. bovis* PPD as determined by the caudal fold test. Caudal fold skin test responses (means  $\pm$  standard errors) by control ( $n = 10$ ), *M. kansasii*-infected ( $n = 4$ ), and *M. bovis*-infected ( $n = 9$ ) cattle to *M. bovis* PPD. Responses represent the change in skin thickness relative to preinjection CFT values. The letters a to c indicate responses that differ ( $P < 0.05$ ).

(Table 1). All *M. kansasii*-inoculated and noninoculated cattle were considered negative by CCT, as determined by plotting responses on the USDA-approved scattergram for the interpretation of the CCT results (i.e., APHIS, Veterinary Services form 6-22D [39b]). Responses (i.e., by CCT) to both *M. avium* and *M. bovis* PPDs by *M. kansasii*-inoculated cattle exceeded respective responses by noninoculated cattle (Table 1). Skin test responses by *M. kansasii*-inoculated cattle to *M. bovis* PPD did not differ ( $P > 0.05$ ) from respective responses to *M. avium* PPD (Fig. 1), whereas responses by *M. bovis*-inoculated calves to *M. bovis* PPD greatly exceeded ( $P < 0.0001$ ) respective responses to *M. avium* PPD (Table 1).

**Lymphocyte blastogenesis.** As with skin test responses, the ranking of blastogenic responses ( $\Delta$ cpm) resulted in *M. bovis*-inoculated cattle having stronger responses than *M. kansasii*-inoculated cattle and *M. kansasii*-inoculated cattle having stronger responses than noninoculated cattle (Table 2). Mean blastogenic responses to *M. bovis* PPD by *M. kansasii*-inoculated

cattle did not differ ( $P > 0.05$ ) from respective responses to *M. avium* PPD, whereas responses to *M. bovis* PPD by *M. bovis*-inoculated calves greatly exceeded ( $P < 0.001$ ) respective responses to *M. avium* PPD (data not shown). At 129 days postchallenge, the mean ( $\pm$ standard error of the mean) blastogenic responses by *M. bovis*-inoculated calves to rESAT-6-CFP-10 ( $32,577 \pm 4,978$ ) exceeded ( $P < 0.05$ ) respective responses by *M. kansasii*-inoculated ( $2,140 \pm 815$ ) and noninoculated ( $662 \pm 697$ ) calves, with similar differences at 50 days postchallenge.

**Nitrite response.** The stimulation of inducible nitric oxide synthase in macrophages and the subsequent generation of reactive nitrogen intermediates are potent mechanisms of mycobacterial killing (10, 11, 13, 17, 27). As previously demonstrated (43), robust recall nitrite responses, a correlate to NO production, are induced upon *M. bovis* infection (Fig. 2). At 15 days postchallenge, the in vitro production of nitrite by PBMC from *M. kansasii*-inoculated calves in response to *M. bovis* PPD exceeded ( $P < 0.05$ ) respective responses by *M. bovis*-inoculated and noninoculated calves (Fig. 2B). At other time points after challenge (with one exception), nitrite responses by PBMC from *M. bovis*-inoculated calves exceeded ( $P < 0.05$ )

TABLE 1. Comparative cervical skin tuberculin test responses

Infection status (no. of cattle)	Mean $\pm$ SE change in skin thickness (mm) <sup>a</sup>		Status <sup>b</sup>
	<i>M. avium</i> PPD	<i>M. bovis</i> PPD	
Noninfected (5)	1.5 $\pm$ 0.53 A	0.5 $\pm$ 0.15 A	All negative
<i>M. kansasii</i> infected (4)	5.4 $\pm$ 0.52 B	4.6 $\pm$ 0.28 B	All negative
<i>M. bovis</i> infected (9)	4.3 $\pm$ 0.5 B	26.3 $\pm$ 3.65 C	All reactors

<sup>a</sup> Animals received 0.1 ml (100  $\mu$ g) of *M. bovis* PPD and 0.1 ml (40  $\mu$ g) of *M. avium* PPD in the midcervical region according to guidelines described in USDA, APHIS circular 91-45-01 (39a). Skin thickness changes (mm) in response to PPD stimulation (mycobacterial origin indicated) are presented as the means  $\pm$  standard errors at 72 h after injection minus the skin thickness prior to injection. The letters A through C indicate responses that differ ( $P < 0.01$ ) for a specific stimulation (i.e., vertical comparisons). The same letter indicates that the responses did not differ.

<sup>b</sup> Change in skin thickness values for individual animals were plotted on a scattergram for the interpretation of CCT results (USDA, APHIS, Veterinary Services form 6-22D, cattle bison interpretation [39b]) and characterized as negative or suspect for TB or reactive to tuberculosis exposure.

TABLE 2. Lymphocyte blastogenesis responses to *M. bovis* PPD stimulation

Infection status	Lymphocyte blastogenesis $\Delta$ cpm (mean $\pm$ SE) at <sup>a</sup> :		
	Preinoculation	Day 50 postinoculation	Day 124 postinoculation
Noninfected	33.3 $\pm$ 80 A	-425 $\pm$ 812 A	-284 $\pm$ 980 A
<i>M. kansasii</i> infected	-127 $\pm$ 171 A	4,676 $\pm$ 2,014 B	9,123 $\pm$ 4,067 B
<i>M. bovis</i> infected	52 $\pm$ 105 A	17,836 $\pm$ 3,378 C	48,741 $\pm$ 5,409 C

<sup>a</sup> Shown are mean ( $\pm$ standard error) lymphocyte blastogenic responses ( $\Delta$ cpm = *M. bovis* PPD stimulation - no stimulation) from noninfected ( $n = 10$ ), *M. kansasii*-infected ( $n = 4$ ), and *M. bovis*-infected ( $n = 9$ ) cattle. The letters A through C indicate responses that differ ( $P < 0.05$ ) for a specific time after inoculation (i.e., vertical comparisons). The same letter indicates that the responses did not differ.




FIG. 2. Longitudinal nitrite production to mycobacterial antigens. Blood mononuclear cells were isolated from control ( $n = 10$ ), *M. kansasii*-infected ( $n = 4$ ), and *M. bovis*-infected ( $n = 9$ ) cattle at the indicated time points after challenge. Isolates were cultured for 72 h with medium alone, 1  $\mu\text{g/ml}$  rESAT-6-CFP-10, or 5  $\mu\text{g/ml}$  PPDs, and supernatants were harvested for analysis of nitrite (Griess reaction) as an indication of NO production. Values are presented as mean ( $\pm$  standard error) responses to rESAT-6-CFP-10 (A) or *M. bovis* PPD (B) stimulation minus the response to medium alone. The letters a to c indicate responses that differ ( $P < 0.05$ ) for each respective time point after challenge.

respective responses by *M. kansasii*-inoculated and noninoculated calves (Fig. 2). The nitrite responses by *M. kansasii*-inoculated calves to rESAT-6-CFP-10 and to *M. bovis* PPD exceeded ( $P < 0.05$ ) respective responses by noninoculated calves at 29, 50, and 85 days postchallenge. Mean nitrite responses by *M. kansasii*-inoculated calves to *M. bovis* PPD did not differ ( $P > 0.05$ ) from respective responses to *M. avium* PPD, whereas responses by *M. bovis*-inoculated calves to *M. bovis* PPD exceeded ( $P < 0.05$ ) respective responses to *M. avium* PPD (data not shown).

**IFN- $\gamma$  response.** The evaluation of antigen-specific IFN- $\gamma$  production is widely accepted as an immunodiagnostic tool for the detection of tuberculous cattle (48, 49) and humans (30). At 15 days postchallenge, as with the nitrite responses, IFN- $\gamma$  responses to *M. bovis* PPD by PBMC from *M. kansasii*-inoculated calves exceeded ( $P < 0.05$ ) respective responses by *M. bovis*-inoculated and noninoculated calves (Fig. 3B). At 15 days postchallenge, IFN- $\gamma$  responses to rESAT-6-CFP-10 by




FIG. 3. Longitudinal IFN- $\gamma$  production to mycobacterial antigens. Blood mononuclear cells were isolated from control ( $n = 10$ ), *M. kansasii*-infected ( $n = 4$ ), and *M. bovis*-infected ( $n = 9$ ) cattle at the indicated time points after the challenge. Isolates were cultured for 48 h with medium alone, 1  $\mu\text{g/ml}$  rESAT-6-CFP-10, or 5  $\mu\text{g/ml}$  PPDs, and supernatants were harvested for the analysis of IFN- $\gamma$  by ELISA. Values are presented as mean ( $\pm$  standard error) responses to rESAT-6-CFP-10 (A) or *M. bovis* PPD (B) stimulation minus the response to medium alone. Letters a to c indicate responses that differ ( $P < 0.05$ ) for each respective time point after challenge. The same letter indicates that the responses did not differ.

*M. kansasii*- and *M. bovis*-inoculated calves exceeded ( $P < 0.05$ ) respective responses by noninoculated calves. At all other time points after challenge (with one exception), IFN- $\gamma$  responses by PBMC from *M. bovis*-inoculated calves exceeded ( $P < 0.05$ ) respective responses by *M. kansasii*-inoculated and noninoculated calves (Fig. 3). In general, the mean nitrite (Fig. 2) and IFN- $\gamma$  (Fig. 3) responses by *M. kansasii*-inoculated calves were intermediate in magnitude between those of *M. bovis*-inoculated and noninoculated calves. The evaluation of individual responses (Fig. 4) revealed that two of the four *M. kansasii*-inoculated cattle (animals 168 and 321) had robust IFN- $\gamma$  responses to rESAT-6-CFP-10 throughout the study, whereas the other two animals had poor to no responses to rESAT-6-CFP-10. These findings, while from a limited number of cattle ( $n = 4$ ), demonstrate the potential for interference that exists in the interpretation of results from improved




FIG. 4. Effects of the skin test on in vitro IFN-γ production by individual *M. kansasii*-sensitized cattle in response to mycobacterial antigens. Blood mononuclear cells were isolated from *M. kansasii*-infected cattle at the indicated time points after challenge (x axis) and cultured for 48 h with medium alone, 1 μg/ml rESAT-6-CFP-10, or 5 μg/ml PPDs, and supernatants were harvested for analysis of IFN-γ by ELISA. Values are presented as individual responses (in the key, numbers next to symbols refer to the animals' numbers) to rESAT-6-CFP-10 (A) or *M. bovis* PPD (B) stimulation (stim.) minus the response to the medium alone. Arrows below "CFT" and "CCT" indicate time points of injection of PPDs for the caudal fold and comparative cervical skin tests, respectively.

TB tests that use defined antigens. Responses to *M. bovis* PPD, however, were detected for each of the four *M. kansasii*-inoculated animals (Fig. 4). Linear regression analysis revealed that individual IFN-γ responses by *M. kansasii*-infected calves to *M. bovis* PPD correlated to respective *M. avium* PPD responses (Pearson's product-moment correlations,  $r = 0.93$ ;  $P < 0.0001$ ). However, 16/48 tests were considered positive (including positive responses by each of the four animals) using a Bovigam kit *M. bovis* PPD minus *M. avium* PPD cutoff value of >0.1 optical density unit, demonstrating the potential for falsely characterizing the animal as a TB reactor.

The magnitude of IFN-γ responses to both *M. bovis* PPD and rESAT-6-CFP-10 was reduced following the injection of PPDs for skin tests (Fig. 4). The reduction in the response to rESAT-6-CFP-10 followed an initial increase 3 days after the injection of PPDs. The administration of PPDs for the second skin test (i.e., CCT) elicited a response to rESAT-6-CFP-10

by a previously nonresponding *M. kansasii*-inoculated animal (Fig. 4, animal 86).

**Antibody response.** Recent studies have indicated that serum antibody to mycobacterial infection, either natural or experimental, is detectable relatively early after infection (24, 44). The use of an ELISA-based assay for LAM demonstrated that *Mycobacterium*-specific antibody was detected as early as 50 days after challenge for *M. kansasii*-infected cattle and 124 days after challenge for *M. bovis*-infected cattle (Table 3). Responses by *M. bovis*-infected cattle exceeded ( $P < 0.05$ ) respective responses by *M. kansasii*-infected cattle at 124 days after the challenge but not at 50 days after the challenge. The early LAM response by *M. kansasii* relative to *M. bovis* infection may be due to the larger challenge dose (i.e.,  $4 \times 10^8$  CFU for *M. kansasii* versus  $4 \times 10^4$  CFU for *M. bovis*). By immunoblotting (Fig. 5), the specific antibody to MPB83 was detectable at 112 and 124 days after *M. kansasii* challenge. It should be noted that significant responses to MPB83 by *M. kansasii*-infected cattle were detected only after the injection of PPDs for the comparative cervical skin test. A low level of background, nonspecific reactivity was detected in each of the *M. kansasii*-inoculated animals prior to skin testing. Antibody to MPB83 was elicited as early as 58 days after *M. bovis* inoculation (Fig. 5), and responses were more robust than those elicited upon *M. kansasii* infection (Fig. 6). In contrast to cell-mediated responses to rESAT-6-CFP-10, responses to ESAT-6 and/or CFP-10 were not detected in sera from *M. kansasii*-sensitized cattle, as determined by MAPIA and immunoblotting (data not shown). However, these antigens elicited antibody responses in cattle infected with *M. bovis*. Using MAPIA, antibodies to *M. bovis* PPD were detected in sera from three of four *M. kansasii*-infected cattle and all *M. bovis*-infected cattle. Other antigens included in the MAPIA did not react with sera from *M. kansasii*-infected cattle (data not shown).

**DISCUSSION**

The present findings demonstrate that while the experimental challenge of cattle with *M. kansasii* failed to cause clinical disease, it did induce detectable immune responses that potentially confound the interpretation of traditional (i.e., skin test) and modern (i.e., IFN-γ-based and antibody-based) TB tests. The Mantoux test for humans, as with the CFT for cattle,

TABLE 3. Response kinetics of serum antibody to mycobacterial LAM-enriched antigen

Infection status	S/P ratio (mean ± SE) of serum responses <sup>a</sup>		
	Preinoculation	Day 50 postinoculation	Day 124 postinoculation
Noninfected	-0.06 ± 0.03 A	0.00 ± 0.05 A	0.04 ± 0.14 A
<i>M. kansasii</i> infected	0.05 ± 0.06 A	0.55 ± 0.26 B	0.76 ± 0.38 B
<i>M. bovis</i> infected	-0.10 ± 0.11 A	0.01 ± 0.03 A	1.64 ± 0.19 C

<sup>a</sup> Shown are S/P ratio means (± standard errors) of serum ELISA responses from noninfected ( $n = 10$ ), *M. kansasii*-infected ( $n = 4$ ), and *M. bovis*-infected ( $n = 9$ ) cattle. The S/P ratios of test samples were calculated from absorbency values using the following formula: sample - negative control/positive control - negative control. The letters A through C indicate responses that differ ( $P < 0.05$ ) for a specific time after inoculation (i.e., vertical comparisons). The same letter indicates that the antibody responses did not differ.




FIG. 5. Western blot analysis of antibody responses to MPB83. Preparative immunoblots of *M. bovis* MPB83 antigen probed with sera from cattle experimentally infected with either *M. kansasii*, *M. bovis*, or serum from a noninfected animal (control). Molecular mass is indicated to the left of the top blot (uniform for each blot), days after infection are shown along the top, animal number and infection status are shown on the right, and time points of injection of PPD(s) for skin tests are shown at the bottom. NS, no sample.

is based on in vivo reactivity to a single tuberculin produced from an *M. tuberculosis* complex mycobacterium. Unlike with many TB testing strategies for cattle, the Mantoux test is not followed up with a secondary skin test (e.g., CCT) designed to differentiate between *M. tuberculosis* complex responses and responses induced by exposure to *M. avium* and/or other non-tuberculous mycobacteria. Based on the single tuberculin test (i.e., CFT), all cattle inoculated with *M. kansasii* in this study would be considered TB responders. Nonspecific reactions are not uncommon with complex antigens such as PPDs. A recently approved IFN- $\gamma$ -based test for use with whole-blood samples from humans (Quantiferon Gold; Cellestis) appears promising for clinical use and relies on reactivity to ESAT-6 and CFP-10 (16). Despite a proven record of the improved specificity of these antigens over those of tuberculin-based tests, the present findings indicate that caution may be warranted in the interpretation of responses to ESAT-6 and CFP-10 antigens, at least in certain (presumably rare) instances, as demonstrated with *M. kansasii* sensitization.

*Mycobacterium kansasii* is genetically heterogenous with certain genotypes associated with clinical disease in humans (1, 32). Currently, there are five distinct groups defined by sequences in the 16S-23S rRNA intergenic spacer region of the bacterial DNA. Specific genotypes of bovine isolates, however,




FIG. 6. Relative intensities of responses to MPB83 as measured by MAPIA. Sera collected from *M. bovis*-infected (circles;  $n = 9$ ) and *M. kansasii*-infected (triangles;  $n = 4$ ) cattle 112 days after inoculation were evaluated by MAPIA for reactivity to mycobacterial antigens. For comparison, the intensities of bands of reactivity to MPB83 were determined by densitometry and are presented as absorbency values.

have not been characterized accordingly. A relatively large challenge dose was used to induce a response to *M. kansasii*. Challenge doses achieved under field conditions are not clear; however, cattle with lesions associated with *M. kansasii* are occasionally detected. Fortunately, an immune response was induced with this challenge dose, thereby meeting a primary goal of this study. If responses had not been induced, as may have occurred with lower doses, then the potential for interference with TB tests would not have been recognized. The *M. kansasii* strain used in the present study was isolated from a tuberculous lesion (i.e., pyogranuloma) detected upon routine slaughter surveillance. The isolate had 100% identity with the subtype 1 genotype, most commonly associated with disease in immunocompetent humans. Other mycobacteria were not isolated from this lesion, and the animal of origin was considered negative for TB. Despite its associations with clinical disease, the intratonsillar inoculation of four calves in the present study did not result in the clinical manifestation of disease, gross or microscopic lesions, or reisolation of the mycobacterium from the animals, all of which are indicative of effective clearance of the organism. Thus, immune responses were elicited and maintained throughout the study with an apparent absence of ongoing, persistent infection. In contrast, humans with clinical disease due to *M. kansasii* infection maintain a state of constant or increasing antigen stimulation, as occurs with chronic TB infection. With ongoing clinical disease, mycobacterial antigens such as ESAT-6, CFP-10, and MPB83 are continually produced and available for immune stimulation of the host. In our studies with samples from humans, we have found strong antibody responses against MPB83 in immunocompetent patients with *M. kansasii*-positive pulmonary disease (data not shown). The present findings for cattle demonstrate that immune responses to ESAT-6, CFP-10, and MPB83 may be evoked by *M. kansasii* sensitization even without persistent infection and clinical disease. While only a limited number of animals were used for *M. kansasii* inoculation ( $n = 4$ ), the number was adequate to demonstrate that cattle exposed to *M. kansasii* may respond to *M. bovis* antigens. Also, as evidenced

by serum reactivity to MPB83 following skin tests, initially weak antibody responses in *M. kansasii*-inoculated cattle are further stimulated by injection of PPDs, although antibody levels remained significantly lower than those detected in sera from cattle infected with *M. bovis*. These findings further substantiate the stealthy nature of preexisting mycobacterial exposure events that elicit low-level and potentially undetectable responses to epitopes and/or antigens contained within tuberculous mycobacteria. These low-level responses may then be boosted to detectable levels by the injection of tuberculin for skin testing.

Molecular and traditional microbiological methods are readily available to distinguish between *M. bovis* and *M. kansasii* infection upon collection of tissues at necropsy. The isolation of nontuberculous mycobacteria (e.g., *M. kansasii*) does not result in the condemnation of carcasses from human consumption. More importantly, the detection of *M. bovis* in cattle results in serious regulatory action, including costly epidemiologic studies, increased testing, and potentially the loss of TB-free status for states or regions and the loss of trading partners. Thus, it is critical that *M. bovis* infection be differentiated from infection/sensitization resulting from exposure to nontuberculous mycobacteria. Over the past 4.25 years, 26,480 (16,506 from cattle) diagnostic specimens have been cultured by the National Veterinary Services Laboratories for the recovery of mycobacterial pathogens. Of these, *M. kansasii* was isolated from only 29 cases, 14 of these from cattle. These findings demonstrate that disease resulting from *M. kansasii* infection is exceedingly rare. However, the number of animals that are exposed in the field to *M. kansasii* and do not develop disease associated with exposure to the organism is not known. As demonstrated from the present study, *M. kansasii* exposure of cattle may induce sensitization without disease. More importantly, this exposure may elicit specific responses that confound the interpretation of antemortem bovine TB tests. In particular, this exposure may interfere with the interpretation of improved TB tests that use "TB-specific" antigens (i.e., ESAT-6, CFP-10, and MPB83). These findings demonstrate one explanation for false-positive responses to TB tests that rely on responses to purportedly *M. tuberculosis* complex-specific antigens.

#### ACKNOWLEDGMENTS

We thank Mike Howard, Peter Lasley, Rebecca Lyon, Jessica Pollock, Todd Stuber, and Shelly Zimmerman for excellent technical support. We also thank Richard Auwerda, Doug Ewing, Andrew Gibson, Don Hackbarth, Todd Holtz, Terry Krausman, David Panthen, Brian Pottebaum, Don Robinson, Jay Steffen, Johann Thiel, Wayne Varland, and Larry Wright for excellent animal care.

#### REFERENCES

- Alcaide, F., I. Richter, C. Bernasconi, B. Springer, C. Hagenau, R. Schulze-Robbecke, E. Tortoli, R. Martin, E. C. Böttger, and A. Telenti. 1997. Heterogeneity and clonality among isolates of *Mycobacterium kansasii*: implications for epidemiological and pathogenicity studies. *J. Clin. Microbiol.* **35**: 1959–1964.
- Arend, S. M., P. de Haas, E. Leyten, I. Rosenkrands, L. Rigouts, P. Andersen, W. Mijs, J. T. van Dissel, and D. van Soolingen. 2005. ESAT-6 and CFP-10 in clinical versus environmental isolates of *Mycobacterium kansasii*. *J. Infect. Dis.* **191**:1301–1310.
- Arend, S. M., E. Cerda de Palou, P. de Haas, R. Janssen, M. A. Hoeve, E. M. Verhard, T. H. Ottenhoff, D. van Soolingen, and J. T. van Dissel. 2004. Pneumonia caused by *Mycobacterium kansasii* in a series of patients without recognised immune defect. *Clin. Microbiol. Infect.* **10**:738–748.
- Arend, S. M., K. E. van Meijgaarden, K. de Boer, E. C. de Palou, D. van Soolingen, T. H. Ottenhoff, and J. T. van Dissel. 2002. Tuberculin skin testing and in vitro T cell responses to ESAT-6 and culture filtrate protein 10 after infection with *Mycobacterium marinum* or *M. kansasii*. *J. Infect. Dis.* **186**:1797–1807.
- Arend, S. M., T. H. Ottenhoff, P. Andersen, and J. T. van Dissel. 2001. Uncommon presentations of tuberculosis: the potential value of a novel diagnostic assay based on the *Mycobacterium tuberculosis*-specific antigens ESAT-6 and CFP-10. *Int. J. Tuberc. Lung Dis.* **5**:680–686.
- Bannantine, J., and J. R. Stabel. 2000. HspX is present within *Mycobacterium paratuberculosis*-infected macrophages and is recognized by sera from some infected cattle. *Vet. Microbiol.* **76**:343–358.
- Bolin, C. A., D. L. Whipple, K. V. Khanna, J. M. Risdahl, P. K. Peterson, and T. W. Molitor. 1997. Infection of swine with *Mycobacterium bovis* as a model of human tuberculosis. *J. Infect. Dis.* **176**:1559–1566.
- Buddle, B. M., A. R. McCarthy, T. J. Ryan, J. M. Pollock, H. M. Vordermeier, R. G. Hewinson, P. Andersen, and G. W. de Lisle. 2003. Use of mycobacterial peptides and recombinant proteins for the diagnosis of bovine tuberculosis in skin test-positive cattle. *Vet. Rec.* **153**:615–620.
- Burton, J. L., and M. E. Kehrli. 1996. Effects of dexamethasone on bovine circulating T lymphocyte populations. *J. Leukoc. Biol.* **59**:90–99.
- Chan, J., K. Tanaka, D. Carroll, J. Flynn, and B. R. Bloom. 1995. Effects of nitric oxide synthase inhibitors on murine infection with *Mycobacterium tuberculosis*. *Infect. Immun.* **63**:736–740.
- Chan, J., Y. Xing, R. Magliozzo, and B. R. Bloom. 1992. Killing of virulent *Mycobacterium tuberculosis* by reactive nitrogen intermediates produced by activated murine macrophages. *J. Exp. Med.* **175**:1111–1122.
- Cole, S. T., R. Brosch, J. Parkhill, T. Garnier, C. Churcher, D. Harris, S. V. Gordon, et al. 1998. Deciphering the biology of *Mycobacterium tuberculosis* from the complete genome sequence. *Nature* **393**:537–544.
- Denis, M. 1991. Interferon-gamma-treated murine macrophages inhibit growth of tubercle bacilli via the generation of reactive nitrogen intermediates. *Cell. Immunol.* **132**:150–157.
- Evans, A. J., A. J. Crisp, R. B. Hubbard, A. Colville, S. A. Evans, and I. D. Johnston. 1996. Pulmonary *Mycobacterium kansasii* infection: comparison of radiological appearances with pulmonary tuberculosis. *Thorax* **51**:1243–1247.
- Evans, S. A., A. Colville, A. J. Evans, A. J. Crisp, and I. D. Johnston. 1996. Pulmonary *Mycobacterium kansasii* infection: comparison of the clinical features, treatment and outcome with pulmonary tuberculosis. *Thorax* **51**:1248–1252.
- Ferrara, G., M. Losi, M. Meacci, B. Meccugni, R. Piro, P. Roversi, B. M. Bergamini, R. D'Amico, P. Marchegiano, F. Rumpianesi, L. M. Fabbri, and L. Richeldi. 2005. Routine hospital use of a commercial whole blood interferon-gamma assay for tuberculosis infection. *Am. J. Respir. Crit. Care Med.* **172**:631–635.
- Flesch, I. E., and S. H. Kaufmann. 1991. Mechanisms involved in mycobacterial growth inhibition by gamma interferon-activated bone marrow macrophages: role of reactive nitrogen intermediates. *Infect. Immun.* **59**:3213–3218.
- Gey van Pittius, N. C., R. M. Warren, and P. D. van Helden. 2002. ESAT-6 and CFP-10: what is the diagnosis? *Infect. Immun.* **70**:6509–6511.
- Gey van Pittius, N. C., J. Gamielien, W. Hide, G. D. Brown, R. J. Siezen, and A. D. Beyers. 2001. The ESAT-6 gene cluster of *Mycobacterium tuberculosis* and other high G+C Gram-positive bacteria. *Genome Biol.* **2**:0044–0048.
- Greenwald, R., J. Esfandiari, S. Lesellier, R. Houghton, J. Pollock, C. Aagaard, P. Andersen, R. G. Hewinson, M. Chambers, and K. Lyashchenko. 2003. Improved serodetection of *Mycobacterium bovis* infection in badgers (*Meles meles*) using multi-antigen test formats. *Diagn. Microbiol. Infect. Dis.* **46**:197–203.
- Hughes, M. S., N. W. Ball, J. McCarroll, M. Erskine, M. J. Taylor, J. M. Pollock, R. A. Skuce, and S. D. Neill. 2005. Molecular analyses of mycobacteria other than the *M. tuberculosis* complex isolated from Northern Ireland cattle. *Vet. Microbiol.* **108**:101–112.
- Karlson, A. G. 1962. Non-specific or cross sensitivity reactions to tuberculin in cattle. *Adv. Vet. Sci.* **7**:147–181.
- Keet, D. F., N. P. Kriek, R. G. Bengis, and A. L. Michel. 2001. Tuberculosis in kudus (*Tragelaphus strepsiceros*) in the Kruger National Park. *Onderstepoort J. Vet. Res.* **68**:225–230.
- Koets, A. P., V. P. Rutten, M. de Boer, D. Bakker, P. Valentin-Weigand, and W. van Eden. 2001. Differential changes in heat shock protein-, lipaarabinomannan-, and purified protein derivative-specific immunoglobulin G1 and G2 isotype responses during bovine *Mycobacterium avium* subsp. *paratuberculosis* infection. *Infect. Immun.* **69**:1492–1498.
- Lightbody, K. A., R. A. Skuce, S. D. Neill, and J. M. Pollock. 1998. Mycobacterial antigen-specific antibody responses in bovine tuberculosis: an ELISA with potential to confirm disease status. *Vet. Rec.* **142**:295–300.
- Lyashchenko, K. P., M. Singh, R. Colangeli, and M. L. Gennaro. 2000. A multi-antigen print immunoassay for the development of serological diagnosis of infectious diseases. *J. Immunol. Methods* **242**:91–100.
- MacMicking, J. D., R. J. North, R. LaCourse, J. S. Mudgett, S. K. Shah, and



- C. F. Nathan. 1997. Identification of nitric oxide synthase as a protective locus against tuberculosis. *Proc. Natl. Acad. Sci. USA* **94**:5243–5248.
28. McNair, J., D. M. Corbett, R. M. Girvin, D. P. Mackie, and J. M. Pollock. 2001. Characterization of the early antibody response in bovine tuberculosis: MPB83 is an early target with diagnostic potential. *Scand. J. Immunol.* **53**:365–371.
29. Menon, S. A., M. J. Wannemuehler, G. G. Mahairas, and F. C. Minion. 2002. Mycobacterial ESAT-6 protein enhances mouse IFN- $\gamma$  responses to *Mycobacterium hypopneumoniae* P71 protein. *J. Interferon Cytokine Res.* **22**:807–813.
30. Pai, M., L. W. Riley, and J. M. Colford. 2004. Interferon- $\gamma$  assays in the immunodiagnosis of tuberculosis: a systematic review. *Lancet Infect. Dis.* **4**:761–776.
31. Palmer, M. V., D. L. Whipple, and S. C. Olsen. 1999. Development of a model of natural infection with *Mycobacterium bovis* in white-tailed deer. *J. Wildl. Dis.* **35**:450–457.
32. Picardeau, M., G. Prod'Hom, L. Raskine, M. P. LePennec, and V. Vincent. 1997. Genotypic characterization of five subspecies of *Mycobacterium kansasii*. *J. Clin. Microbiol.* **35**:25–32.
33. Pollock, J. M., and P. Andersen. 1997. The potential of the ESAT-6 antigen secreted by virulent mycobacteria for specific diagnosis of tuberculosis. *J. Infect. Dis.* **175**:1251–1254.
34. Pollock, J. M., R. M. Girvin, K. A. Lightbody, R. A. Clements, S. D. Neill, B. M. Buddle, and P. Andersen. 2000. Assessment of defined antigens for the diagnosis of bovine tuberculosis in skin test-reactor cattle. *Vet. Rec.* **146**:659–665.
35. Rajaraman, V., B. J. Nonnecke, S. T. Franklin, D. C. Hammell, and R. L. Horst. 1998. Effect of vitamins A and E on nitric oxide production by blood mononuclear leukocytes from neonatal calves fed milk replacer. *J. Dairy Sci.* **81**:3278–3285.
36. Ravn, P., M. E. Munk, Å. B. Andersen, B. Lundgren, J. D. Lundgren, L. N. Nielsen, A. Kok-Jensen, P. Andersen, and K. Weldingh. 2005. Prospective evaluation of a whole-blood test using *Mycobacterium tuberculosis*-specific antigens ESAT-6 and CFP-10 for diagnosis of active tuberculosis. *Clin. Diagn. Lab. Immunol.* **12**:491–496.
37. Roth, A., M. Fischer, M. E. Hamid, S. Michalke, W. Ludwig, and H. Mauch. 1998. Differentiation of phylogenetically related slowly growing mycobacteria based on 16S-23S rRNA gene internal transcribed spacer sequences. *J. Clin. Microbiol.* **36**:139–147.
38. Schmitt, S. M., S. D. Fitzgerald, T. M. Cooley, C. S. Bruning-Fann, L. Sullivan, D. Berry, T. Carlson, R. B. Minnis, J. B. Payeur, and J. Sikarskie. 1997. Bovine tuberculosis in free-ranging white-tailed deer from Michigan. *J. Wildl. Dis.* **33**:749–758.
39. Skjöt, R. L. V., I. Brock, S. M. Arend, M. E. Munk, M. Theisen, T. H. M. Ottenhoff, and P. Andersen. 2002. Epitope mapping of the immunodominant antigen TB10.4 and the two homologous proteins TB10.3 and TB12.9, which constitute a subfamily of the *esat-6* gene family. *Infect. Immun.* **70**:5446–5453.
- 39a. USDA, APHIS. 1999. Bovine tuberculosis eradication uniform methods and rules, p. 1–34. U.S. Government Printing Office, Washington, D.C.
- 39b. USDA, APHIS, Veterinary Services. 1999. Scattergram for interpretation of the comparative cervical test. Veterinary Services form 6-22D. USDA, APHIS, Ames, Iowa.
40. Vordermeier, H. M., A. Whelan, P. J. Cockle, L. Farrant, N. Palmer, and R. G. Hewinson. 2001. Use of synthetic peptides derived from the antigens ESAT-6 and CFP-10 for differential diagnosis of bovine tuberculosis in cattle. *Clin. Diagn. Lab. Immunol.* **8**:571–578.
41. Vosloo, W., P. Tippoo, J. E. Hughes, N. Harriman, M. Emms, D. W. Beatty, H. Zappe, and L. M. Steyn. 1997. Characterisation of a lipoprotein in *Mycobacterium bovis* (BCG) with sequence similarity to the secreted protein MPB70. *Gene* **188**:123–128.
42. Waters, W. R., M. V. Palmer, and D. L. Whipple. 2002. *Mycobacterium bovis*-infected white-tailed deer (*Odocoileus virginianus*): detection of immunoglobulin specific to crude mycobacterial antigens by ELISA. *J. Vet. Diagn. Invest.* **14**:470–475.
43. Waters, W. R., M. V. Palmer, D. L. Whipple, M. P. Carlson, and B. J. Nonnecke. 2003. Diagnostic implications of antigen-induced gamma interferon, nitric oxide, and tumor necrosis factor alpha production by peripheral blood mononuclear cells from *Mycobacterium bovis*-infected cattle. *Clin. Diagn. Lab. Immunol.* **10**:960–966.
44. Waters, W. R., J. M. Miller, M. V. Palmer, J. R. Stabel, D. E. Jones, K. A. Koistinen, E. M. Steadham, M. J. Hamilton, W. C. Davis, and J. P. Bannantine. 2003. Early induction of humoral and cellular immune responses during experimental *Mycobacterium avium* subsp. *paratuberculosis* infection of calves. *Infect. Immun.* **71**:5130–5138.
45. Waters, W. R., B. J. Nonnecke, M. V. Palmer, S. Robbe-Austermann, J. P. Bannantine, J. R. Stabel, D. L. Whipple, J. B. Payeur, D. M. Estes, J. E. Pitzer, and F. C. Minion. 2004. Use of recombinant ESAT-6:CFP-10 fusion protein for differentiation of infections of cattle by *Mycobacterium bovis* and by *M. avium* subsp. *avium* and *M. avium* subsp. *paratuberculosis*. *Clin. Diagn. Lab. Immunol.* **11**:729–735.
46. Waters, W. R., M. V. Palmer, J. P. Bannantine, D. L. Whipple, R. Greenwald, J. Esfandiari, P. Andersen, J. McNair, J. M. Pollock, and K. P. Lyashchenko. 2004. Antigen recognition by serum antibodies in white-tailed deer (*Odocoileus virginianus*) experimentally infected with *Mycobacterium bovis*. *Clin. Diagn. Lab. Immunol.* **11**:849–855.
47. Winters, A., C. Driver, M. Macaraig, C. Clark, S. S. Munsiff, C. Pichardo, J. Driscoll, M. Salfinger, B. Kreiswirth, J. Jereb, P. LoBue, and M. Lynch. 2005. Human tuberculosis caused by *Mycobacterium bovis*—New York City, 2001–2004. *Morb. Mortal. Wkly. Rep.* **54**:605–608.
48. Wood, P. R., L. A. Corner, J. S. Rothel, C. Baldock, S. L. Jones, D. B. Cousins, B. S. McCormick, B. R. Francis, J. Creepeer, and N. E. Tweddle. 1991. Field comparison of the interferon-gamma assay and the intradermal tuberculin test for the diagnosis of bovine tuberculosis. *Aust. Vet. J.* **68**:286–290.
49. Wood, P. R., and J. S. Rothel. 1994. In vitro immunodiagnostic assays for bovine tuberculosis. *Vet. Microbiol.* **40**:125–135.